BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy

Beam Therapeutics (NASDAQ:BEAM) is 1 of the astir promising mid-cap healthcare stocks nether $50.

On December 9, H.C. Wainwright expert Patrick Trucchio reaffirmed his bullish stance connected Beam Therapeutics (NASDAQ:BEAM). He rated the banal Buy with a people terms of $80, implying a important 201% upside.

Dragon Images/Shutterstock.com

Trucchio’s standing and immense upside forecasts are based connected highly encouraging information from Beam Therapeutics’ (NASDAQ:BEAM) BEACON trial. The proceedings results bespeak that risto-cel possesses unsocial imaginable to go an innovative and effectual cure for sickle compartment illness (SCD). This is owed to their quality to change hemoglobin levels, cure anemia, and forestall vaso-occlusive crises.

According to Trucchio, what besides sets Beam Therapeutics (NASDAQ:BEAM) isolated from competitors successful the ex vivo hematology abstraction is its highly differentiated manufacturing process for risto-cel. Using a vein-to-vein timeline successful the process makes it highly scalable and gives the institution a competitory edge.

The statement 1-year median terms people for Beam Therapeutics (NASDAQ:BEAM) is $43. Compared with Trucchio’s forecasts, this represents astir 62% upside from the existent trading level, which remains precise attractive. As of December 19 closing, Beam Therapeutics (NASDAQ:BEAM) banal has received 13 expert ratings, of which 11 were Buy calls, and the remaining 2 were Hold calls.

Beam Therapeutics (NASDAQ:BEAM) is simply a biotechnology institution that develops precision familial medicines and besides engages successful cistron therapies and genome editing research. Since their launch, Beam Therapeutics (NASDAQ:BEAM) has been spearheading the CRISPR-based editing that facilitates the improvement of precocious familial medicines.

While we admit the imaginable of BEAM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.